Firehawk Rapamycin Target Eluting Coronary Stent North American Trial
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1720 participants.
Also called NCT04562532
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,720 participants
- Registry
-
NCT04562532
-
- Other papers using this trial's data
- Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Canada, Denmark, Netherlands
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04562532. Randomized; no masking; primary purpose treatment. Start 2021-02-17 (actual); primary completion 2023-12-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Firehawk Rapamycin Target Eluting Coronary Stent North American Trial
- Acronym
- TARGET-IV_NA
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Microport Firehawk stent
- Intervention (Device)
- 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
- Lead sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Record details
- Record id
cardio:ct-nct04562532- Content hash
f0e279b3be54c6f19120926e7a8a1c8ff06da0888b776d4aa6fd1d7609bcfdb4